Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4436 | congenital malformation Wiki | 0.71 |
| drug1770 | Humor/Salience Wiki | 0.71 |
| drug3922 | Telehealth Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D040921 | Stress Disorders, Traumatic NIH | 0.12 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.12 |
| D004194 | Disease NIH | 0.11 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The investigators thought that the confinement measure took in France could induce an increase in the post traumatic syndrome in the relative of patient hospitalized in ICU during this period indeed the restricted visit and the limited interaction with ICU team are documented risk factors for PTSD in this population. The investigators designed an intervention in order to prevent the effect of the confinement measures on PTSD in relatives named OLAF. In this research the investigators aimed to study the impact on this intervention on PTSD.
Description: To demonstrate the benefits of a comprehensive family approach (OLAF) on the incidence of PTSD observed in 2 close referents of a patient, 6 months after leaving the intensive care unit, in the context of confinement linked to the SARS pandemic- CoV2.
Measure: incidence of PTSD observed 6 months after patient's discharge from the intensive care unit Time: Month 6Description: The incidence of PTSD 6 months after patient's death in the intensive care unit
Measure: incidence of PTSD observed 6 months after patient's death in the intensive care unit Time: Month 6Description: The incidence of PTSD 3 months after the death or discharge from the intensive care unit
Measure: PTSD incidence at month 3 Time: Month 3Description: The incidence of PTSD 12 months after the death or discharge from the intensive care unit
Measure: PTSD incidence at month 12 Time: Month 12Description: The incidence of symptoms of anxiety and / or depression 3 months after death or discharge from the intensive care unit
Measure: Symptoms incidence at month 3 Time: Month 3Description: The incidence of symptoms of anxiety and / or depression 6 months after death or discharge from the intensive care unit
Measure: Symptoms incidence at month 6 Time: Month 6Description: The incidence of symptoms of anxiety and / or depression 12 months after death or discharge from the intensive care unit
Measure: Symptoms incidence at month 12 Time: Month 12Description: The incidence of persistent complicated grief 3 months after death in intensive care
Measure: incidence of persistent complicated grief at month 3 Time: Month 3Description: The incidence of persistent complicated grief 6 months after death in intensive care
Measure: incidence of persistent complicated grief at month 6 Time: Month 6Description: The incidence of persistent complicated grief 12 months after death in intensive care
Measure: incidence of persistent complicated grief at month 12 Time: Month 12Annual Wellness Visits (AWVs) are a type of detailed healthcare checkup to which Medicare beneficiaries are entitled, free of charge, once per year. The purpose of the current study is to assess what content and communication modality results in the most effective messaging campaign to encourage Medicare beneficiaries to schedule their AWVs.
Description: Patient scheduled an AWV appointment
Measure: Proportion of patients who scheduled an AWV appointment Time: 1 month after start of interventionDescription: Patient completed an AWV
Measure: Proportion of patients who completed an AWV visit Time: 3 months after start of interventionDescription: Patient scheduled an AWV appointment
Measure: Proportion of patients who scheduled an AWV appointment Time: 3 months after start of interventionDescription: Patient called one of the phone numbers provided on postcards regarding AWV
Measure: Proportion of patients who initiated contact Time: 3 months after start of interventionDescription: Whether patient AWV was in person or a telehealth visit
Measure: Proportion of visits that were in-person vs. tele-visit Time: 3 months after start of interventionDescription: Cost of campaign for whole study arm divided by number of patients who completed an AWV for that study arm.
Measure: Per patient campaign cost Time: 3 months after start of interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports